Table 2.
IC50, RI, and relative delay rate of drug resistance induced resistant cells.
| Stage | Subgroup | IC50 (nmol/L) | Resistance index | Relative delay rate (%) |
|---|---|---|---|---|
| Parental PC9 | 12.75 ± 2.14 | |||
| Stage 1 | GEF(10 nmol/L) | 20.59 ± 0.25 | 1.63 ± 0.01 | |
| GEF(10 nmol/L)+ SFI(1 mg/mL) | 13.15 ± 0.21 | 1.04 ± 0.01 | 36.13 | |
| GEF(10 nmol/L)+ SFI(4 mg/mL) | 9.06 ± 0.23 | 0.72 ± 0.01 | 56.0 | |
| GEF(10 nmol/L)+ SFI(8 mg/mL) | 7.43 ± 0.06 | 0.58 ± 0.00 | 63.91 | |
| Stage 2 | GEF(10 nmol/L) | 100.08 ± 1.9 | 7.8 ± 0.14 | |
| GEF(10 nmol/L)+ SFI(1 mg/mL) | 36.54 ± 0.48 | 2.82 ± 0.03 | 63.49 | |
| GEF(10 nmol/L)+ SFI(4 mg/mL) | 23.41 | 1.81 ± 0.02 | 76.61 | |
| GEF(10 nmol/L)+ SFI(8 mg/mL) | 18.31 ± 0.05 | 1.44 ± 0.00 | 81.70 | |
| Stage 3 | GEF(10 nmol/L) | 383.53 ± 1.8 | 30.01 ± 0.14 | |
| GEF(10 nmol/L)+ SFI(1 mg/mL) | 232.86 ± 10.31 | 17.33 ± 0.8 | 39.29 | |
| GEF(10 nmol/L)+ SFI(4 mg/mL) | 195.46 ± 1.77 | 15.2 ± 0.13 | 49.04 | |
| GEF(10 nmol/L)+ SFI(8 mg/mL) | 138.03 ± 0.85 | 10.82 ± 0.06 | 64.01 | |
| Stage 4 | GEF(10 nmol/L) | 3988.33 ± 67.5 | 312.78 ± 5.29 | |
| GEF(10 nmol/L)+ SFI(1 mg/mL) | 3766.33 ± 30.23 | 296.31 ± 2.37 | 5.57 | |
| GEF(10 nmol/L)+ SFI(4 mg/mL) | 3357.33 ± 163.83 | 248.54 ± 12.84 | 15.82 | |
| GEF(10 nmol/L)+ SFI(8 mg/mL) | 2903 ± 17.57 | 226.11 ± 1.37 | 27.21 |
Data are expressed as mean ± SEM (n = 3).